HONG KONG – In a move that will give its parent group a debut listing in the U.S., South Korean biotech company Samsung Bioepis said it will aim for a Nasdaq listing. Read More

NEW DELHI – India's Lee Pharma Ltd. may not be granted a compulsory license to manufacture a patented diabetes drug, with the patent regulator suggesting the company has not made a strong enough case for such a license. Read More

HONG KONG – China is speeding up approval times and improving the review process for domestic and imported drugs. The ultimate aim of a series of reforms recently announced by the State Council, akin to the cabinet, is to develop a faster and better approvals system that rewards innovation. Read More

HONG KONG — The findings of a new study of gene regulation by androgen receptor (AR) splice variants (AR-Vs) by U.S and Chinese scientists could provide a pivotal pathway for drug designers to target, in order to disrupt AR-V signaling as a novel strategy for the effective treatment of advanced prostate cancer. Read More

NEW DELHI – Yet another Indian contract research organization (CRO), Hyderabad-based Sipra Labs Ltd., has found itself in hot water after the U.S. FDA issued a warning letter over flaws detected in analytical procedures. Read More